Probiotic use improved acne, rosacea symptoms

[Guide]

An article about improving rosacea with probiotics was written by Whitney Bowe, MD, RRDi MAC Member.

More information on probiotics for rosacea. 

You should really consider taking PROBIOTICS rather than antibiotics for rosacea by considering the following: 

Long term risks and side effects of antibiotic treatment of rosacea. 

Our affiliate store has many probiotic treatments you should consider. 

Reply to this Topic

There is a reply to this topic button somewhere on the device you are reading this post. If you never heard about this topic and you learned about it here first, wouldn't it be a gracious act on your part to show your appreciation for this topic by registering with just your email address and show your appreciation with a post?  And if registering is too much to ask, could you post your appreciation for this topic by finding the START NEW TOPIC button in our guest forum where you don't have to register?  We know how many have viewed this topic because our forum software shows the number of views. However, most rosaceans don't engage or show their appreciation for our website and the RRDi would simply ask that you show your appreciation, please, simply by a post.  

[Guide]

Here's some clinical data and publications on the ability of certain strains (most probiotics are not this advanced - this may be the Align brand).

The first article demonstrates that a specific probiotic reduces systemic and skin inflammation by reducing CRP, inflammatory cytokines, tumor necrosis factor and IL-6. All four are central to rosacea inflammation:

Gut Microbes. 2013 Jul-Aug;4(4):325-39. doi: 10.4161/gmic.25487. Epub 2013 Jun 21.

Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut.

Groeger D¹, O'Mahony L, Murphy EF, Bourke JF, Dinan TG, Kiely B, Shanahan F, Quigley EM.

Author information

• ¹Alimentary Health Ltd., Cork, Ireland.

Abstract

Certain therapeutic microbes, including Bifidobacteria infantis (B. infantis) 35624 exert beneficial immunoregulatory effects by mimicking commensal-immune interactions; however, the value of these effects in patients with non-gastrointestinal inflammatory conditions remains unclear. In this study, we assessed the impact of oral administration of B. infantis 35624, for 6‒8 weeks on inflammatory biomarker and plasma cytokine levels in patients with ulcerative colitis (UC) (n = 22), chronic fatigue syndrome (CFS) (n = 48) and psoriasis (n = 26) in three separate randomized, double-blind, placebo-controlled interventions. Additionally, the effect of B. infantis 35624 on immunological biomarkers in healthy subjects (n = 22) was assessed. At baseline, both gastrointestinal (UC) and non-gastrointestinal (CFS and psoriasis) patients had significantly increased plasma levels of C-reactive protein (CRP) and the pro-inflammatorycytokines tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6) compared with healthy volunteers. B. infantis 35624 feeding resulted in reduced plasma CRP levels in all three inflammatory disorders compared with placebo. Interestingly, plasma TNF-α was reduced in CFS and psoriasis while IL-6 was reduced in UC and CFS. Furthermore, in healthy subjects, LPS-stimulated TNF-α and IL-6 secretion by peripheral blood mononuclear cells (PBMCs) was significantly reduced in the B. infantis 35624-treated groups compared with placebo following eight weeks of feeding. These results demonstrate the ability of this microbe to reduce systemic pro-inflammatory biomarkers in both gastrointestinal and non-gastrointestinal conditions. In conclusion, these data show that the immunomodulatory effects of the microbiota in humans are not limited to the mucosal immune system but extend to the systemic immune system.

This next study, just released shows a clear gut-skin connection:

Benef Microbes. 2014 Jun 1;5(2):129-36. doi: 10.3920/BM2013.0014.

Immune modulation property of Lactobacillus paracasei NCC2461 (ST11) strain and impact on skin defences.

Benyacoub J¹, Bosco N¹, Blanchard C¹, Demont A¹, Philippe D¹, Castiel-Higounenc I², Guéniche A³.

Author information

• ¹Nestle Research Center, Vers-chez-les-Blanc, P.O. Box 44, 1000 Lausanne 26, Switzerland.
• ²L'Oreal Research and Innovation, River Plaza, 25-29 Quai Aulagnier, 92665 Asnières-sur-Seine, France.
• ³LéOreal, Physiology and pharmacology, 89 Rue General Roguet, 92583 Clichy, France.

Abstract

The gut intestinal tract harbours a complex microbiota. Disturbances in the microbiota composition have been associated with several immune dysfunctions such as inflammatory diseases. Specific strains of probiotics have shown to beneficially influence the composition and/or metabolic activity of the endogenous microbiota. Taking advantage of the plasticity of the immune system, the probiotic strain NCC2461 (i.e. ST11 or CNCM I-2116) supports and/or restores homeostasis in reaction to different physiopathological conditions. The potential of NCC2461 to modulate both mucosal and systemic immune functions led us to test its impact on skin physiology. Even though clear mechanisms explaining gut-skin interaction are still lacking, a set of experimental and clinical data reviewed herein have shown that NCC2461 exerts its effects beyond the gut and confers benefits at the skin level. It contributes to the reinforcement ofskin barrier function, decreases skin sensitivity and modulates the skin immune system leading to the preservation of skin homeostasis.

Interesting stuff that is novel to the rosacea community. Most probiotics probably don't have the same effect so you might only take those clinically proven to reduce inflammatory markers and those that have a direct gut-skin interaction.